Delivery Order SPE2DB24D8001-SPE2DB25FLABD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,946.76 to Dakota Drug, Inc., a self-certified small disadvantaged business based in Anoka, Minnesota, for the supply of Methylphenidate ER 54 mg tablets (100 count). The contract is firm fixed price with no set-aside designation and carries an ultimate completion date of July 28, 2025. This delivery order falls under Dakota Drug's larger Indefinite Delivery Contract (SPE2DB24D8001) with DLA Troop Support Medical's ECAT Generation...
- The Defense Logistics Agency awarded a delivery order to Dakota Drug, Inc., a small disadvantaged business based in Anoka, Minnesota, for the supply of Methylphenidate ER 18 mg tablets (100-count units) valued at $3,142.26. This firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and carries no set-aside designation. The award falls under Dakota Drug's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical's ECAT...
- The Defense Logistics Agency awarded a $4.45K firm fixed-price delivery order to Dakota Drug, Inc., a small disadvantaged business based in Anoka, Minnesota, for the supply of Methylphenidate ER 27 mg tablets (100-count units). The contract, executed on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a delivery order under Dakota Drug's larger Indefinite Delivery Contract (SPE2DB24D8001) valued at $999.99M with DLA Troop Support Medical's ECAT Generation V...
- This federal contract award is for the delivery of Methylphenidate ER 36 mg tablets in 100-count packages to the Defense Logistics Agency (DLA). The $3,362.34 firm fixed-price delivery order was awarded to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The award is not set-aside and has an ultimate completion date of May 28, 2025. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the...
- Dakota Drug, Inc., a self-certified small disadvantaged business based in Anoka, Minnesota, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 13, 2025, for the supply of Methylphenidate ER 36 mg tablets in quantities of 100 units. This firm fixed-price delivery order, valued at $6,484.12, is scheduled for completion by August 14, 2025, and represents performance work to be conducted at the contractor's Anoka, Minnesota location. The award utilized no set-aside...
- The Defense Logistics Agency (DLA) awarded a $5,476.61 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4,565,321,317 units of Methylphenidate ER 18 mg tablets. This order falls under Dakota Drug, Inc.'s existing Indefinite Delivery Contract (IDC) SPE2DB24D8001, valued at $999,999,999.00, which allows the company to provide a wide range of pharmaceutical products, medical supplies, and healthcare equipment to...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of 100 bottles of 30mg extended-release methylphenidate tablets to support military medical operations. The contract has a total ceiling value of $1,424.57 and a period of performance through October 16, 2023. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a...
- This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The contract, valued at $2,759.90, is for the delivery of 4,564,754,748 units of 5 mg chewable methylphenidate tablets in 100-count bottles. The contract is a Firm Fixed Price Delivery Order with a performance period ending on May 31, 2024. Dakota Drug, Inc. is an established vendor in the federal marketplace, particularly for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business. The $7,937.66 firm fixed-price contract is for the supply of 4,564,042,715 units of the pharmaceutical product Methylphenidate ER 27 mg tablets with an ultimate completion date of March 22, 2024. No set-aside was used for this award. Dakota Drug, Inc. has over two decades of experience as a prime contractor to the federal government,...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4566327375 - Methylphenidate ER 36 MG Tablets in 100 count bottles. The contract has a ceiling value of $1,664.43 and a period of performance through November 5, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC), SPE2DB24D8001, held by Dakota Drug, Inc. under the DLA Troop Support...
- SPE2DB24D8001Indefinite Delivery Contract
- SPE2DB24D8001-SPE2DB25FLABDDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to Dakota Drug, Inc., a small disadvantaged business based in Anoka, Minnesota, for the supply of Methylphenidate ER 54 mg tablets (100 count) with a ceiling value of $2,055.10. This firm fixed price delivery order was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, with no set-aside designation applied. The contract represents a direct fulfillment of pharmaceutical supply requirements under Dakota Drug's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00 through December 31, 2025. Dakota Drug, Inc. serves as a critical vendor in the federal pharmaceutical supply chain, specializing in medications and medical supplies for U.S. Armed Forces healthcare operations. The company has maintained an established relationship with the DLA since its SAM.gov registration in 2001 and demonstrates broad capabilities across multiple therapeutic categories including neurological, respiratory, cardiovascular, and pain management medications. The delivery of Methylphenidate ER supports military medical facilities' requirements for attention deficit hyperactivity disorder treatment and reflects the company's ongoing role as a strategic supplier within the DLA's medical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 7/22/25 |